These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20864621)

  • 1. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
    Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
    J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
    Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
    Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
    Bennett LL; Turcotte K
    Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
    Umemura K; Kondo K; Ikeda Y; Kobayashi T; Urata Y; Nakashima M
    Br J Clin Pharmacol; 1997 Jun; 43(6):613-8. PubMed ID: 9205821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
    Cox TM
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose, placebo-controlled, phase I study of oral dolasetron.
    Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
    Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
    Peterschmitt MJ; Crawford NPS; Gaemers SJM; Ji AJ; Sharma J; Pham TT
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):86-98. PubMed ID: 32851809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
    Rodríguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
    J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
    Li J; Chen J; Kanamaluru V; Gaemers SJM; Peterschmitt MJ; Hou AW; Xue Y; Turpault S; Rudin D
    Mol Genet Metab; 2020 Feb; 129(2):117-124. PubMed ID: 31924461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T; Henney HR
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.